Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Open accessAbstract
Importance: Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management. Objective: To compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.0 mg (both with diet and physical activity), in people with overweight or obesity. Design, Setting, and Participants: Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338). Interventions: Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity. Participants unable to tolerate 2.4 mg of semaglutide could receive 1.7 mg; participants unable to tolerate 3.0 mg of liraglutide discontinued treatment and could restart the 4-week titration. Placebo groups were pooled (n = 85). Main Outcomes and Measures: The primary end point was percentage change in body weight, and confirmatory secondary end points were achievement of 10% or more, 15% or more, and 20% or more weight loss, assessed for semaglutide vs liraglutide at week 68. Semaglutide vs liraglutide comparisons were open-label, with active treatment groups double-blinded against matched placebo groups. Comparisons of active treatments vs pooled placebo were supportive secondary end points. Results: Of 338 randomized participants (mean [SD] age, 49 [13] years; 265 women [78.4%]; mean [SD] body weight, 104.5 [23.8] kg; mean [SD] body mass index, 37.5 [6.8]), 319 (94.4%) completed the trial, and 271 (80.2%) completed treatment. The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001); weight change with pooled placebo was -1.9%. Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide (70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}], 55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}], and 38.5% vs 6.0% [odds ratio, 8.2 {95% CI, 3.5 to 19.1}], respectively; all P < .001). Proportions of participants discontinuing treatment for any reason were 13.5% with semaglutide and 27.6% with liraglutide. Gastrointestinal adverse events were reported by 84.1% with semaglutide and 82.7% with liraglutide. Conclusions and Relevance: Among adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, added to counseling for diet and physical activity, resulted in significantly greater weight loss at 68 weeks. Trial Registration: ClinicalTrials.gov Identifier: NCT04074161.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In four studies (n = 3087), semaglutide led to a greater percentage of trial discontinuations due to gastrointestinal adverse events relative to placebo (RR 5.36 [95% CI 2.49, 11.55]; P < 0.0001).
“Furthermore, four studies (n = 3087) 16,17,19,20 revealed that semaglutide led to a greater percentage of trial discontinuations due to GI AEs relative to placebo (RR 5.36, [95% CI 2.49, 11.55]; P < 0.0001 [Figure S16]).”
From Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial (2024) · cites this paper as [20]
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredSimilar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [70]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredSemaglutide groups demonstrated a significant reduction in weight at the end of the treatment period for various steps: 14.9% for STEP 1, 16% for STEP 3, 17.4% for STEP 4, 15.2% for STEP 5, and 15.8% for STEP 8.
“the semaglutide groups demonstrated a significant reduction in weight at the end of the treatment period for various steps, namely, 14.9% for STEP 1, 16% for STEP 3, 17.4% for STEP 4, 15.2% for STEP 5, and 15.8% for STEP 8.”
From Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year <scp>STEP</scp> 5 trial (2024) · cites this paper as [20]
The Primary Outcome section reports a 15.8% mean weight reduction with semaglutide at week 68 in STEP 8, significantly greater than with liraglutide. This paper reports the STEP 8 trial; the cited passages do not substantiate the four percentages attributed to STEP 1, STEP 3, STEP 4, and STEP 5. (LLM, conf=0.90)
Experimental — accuracy not yet measuredLong-term adherence to obesity medications in a real-world setting is challenging because the medications are expensive and gastrointestinal adverse events are common.
“Despite the large weight losses with obesity medications, long-term adherence in a real-world setting is challenging since the medications are expensive and gastrointestinal adverse events are common.8,10,11”
From Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial (2024) · cites this paper as [11]
The Adverse Events section reports frequent gastrointestinal events with both medications and some gastrointestinal-related discontinuations. It does not establish that medication costs make long-term adherence difficult in real-world settings; those parts of the claim are unsupported by this trial. (LLM, conf=0.86)
Experimental — accuracy not yet measuredSemaglutide is superior to other GLP-1 receptor agonists for weight loss.
“noted superiority over other GLP-1RAs.”
From Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series (2023) · cites this paper as [30]
The Primary Outcome section reports significantly greater weight loss with semaglutide than with liraglutide at 68 weeks in adults with overweight or obesity without diabetes. The study compared semaglutide with one other GLP-1 receptor agonist, liraglutide; it does not establish superiority over GLP-1 receptor agonists generally. (LLM, conf=0.87)
Experimental — accuracy not yet measured
The lowest studied dose of tirzepatide, 5 mg, results in equivalent weight reduction as the highest doses of its GLP-1 receptor agonist relatives currently approved by FDA for treatment of obesity.
“It is important to note that the lowest studied dose of tirzepatide, 5 mg, has been demonstrated to result in equivalent weight reduction as the highest doses of its GLP-1 receptor agonist relatives that are currently approved by FDA for treatment of obesity (Table 2).27,45”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [45]
The Introduction identifies semaglutide 2.4 mg and liraglutide 3.0 mg as GLP-1 receptor agonists approved for weight management. The Primary Outcome section reports weight reductions with those drugs, but this trial did not study tirzepatide 5 mg or establish that its weight reduction was equivalent to theirs. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredSemaglutide 2.4 mg/week caused greater weight loss than liraglutide 3.0 mg daily in STEP-8, and tirzepatide 15 mg caused greater weight loss than semaglutide 2.4 mg in SURMOUNT-5.
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [70]
In a 68-week comparison, semaglutide 2.4 mg weekly produced greater mean weight loss (-15.8%) than liraglutide 3.0 mg daily (-6.4%) in adults with obesity who received counseling.
“In a 68-week comparison of Sema 2.4 mg weekly versus once-daily Lira 3.0 mg in adults with obesity, all of whom received counseling to achieve a 500 kcal/day energy deficit and meet physical activity recommendations ($150 min/week), the mean weight change from baseline was -15.8% with Sema versus -6.4% with Lira (19).”
From Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (2024) · cites this paper as [19]
In the STEP-8 trial, semaglutide 2.4 mg/week led to greater weight loss (15.8% reduction) compared with liraglutide 3.0 mg once daily (6.4% reduction).
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction);”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [70]
In the STEP 8 trial, semaglutide 2.4 mg had a statistically significant greater effect on reduction in body weight from baseline compared with liraglutide 3.0 mg.
“with the seminal STEP 8 clinical trial reporting semaglutide at the maximal dose of 2.4 mg had a statistically significant greater effect on reduction in body weight from baseline when compared to the maximal dose of liraglutide (3.0 mg) 3”
From Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (2025) · cites this paper as [3]
In the head-to-head STEP 8 trial, semaglutide compared to liraglutide showed a larger weight loss at 68 weeks (15.8% with semaglutide vs 6.4% with liraglutide, P<.001).
“In the head-to-head”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Rubino et al, 2022
In four studies (n = 3087), semaglutide caused a significant reduction in CRP compared with placebo (MD 38.92% [95% CI 43.69, 34.16]; P < 0.00001).
“Four studies (n = 3087) 16,17,19,20 reported a modification in levels of CRP, an indicator of inflammation. Evaluation of the combined analysis showed that semaglutide caused a significant reduction in CRP compared to placebo (MD: 38.92% [95% CI 43.69, 34.16]; P < 0.00001)”
In the head-to-head comparative STEP 8 study, a greater antiobesity effect was observed in the semaglutide treatment group compared with the liraglutide group.
“In the head-to-head comparative STEP 8 study, we observed a greater antiobesity effect in the semaglutide treatment group compared with the liraglutide group.”
Approximately 15% weight loss was observed in overweight and obese, non-diabetic adults across various treatment periods lasting up to 2 years with once-weekly subcutaneous semaglutide 2.4 mg (STEP-1 to STEP-6, STEP-8).
“Generally, approximately 15% weight loss was observed in overweight and obese, non-diabetic adults across various treatment periods, lasting up to 2 years (from STEP-1 to STEP-6, STEP-8) [72,73,74,75,76,77,78,79].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [78]
In a trial of 338 adults with overweight or obesity without type 2 diabetes, once weekly subcutaneous semaglutide resulted in significantly greater weight loss at 68 weeks compared with once daily subcutaneous liraglutide (-15.8% vs -6.4%, difference -9.4 percentage points, 95% CI -12.0 to -6.8, P<0.001).
“One trial of 338 adults with overweight or obesity and without type 2 diabetes found that once weekly subcutaneous semaglutide resulted in significantly greater weight loss at 68 weeks compared with once daily subcutaneous liraglutide 135 (-15.8% with semaglutide v -6.4% with liraglutide (difference -9.4 percentage points (95% confidence interval -12.0 to -6.8), P<0.001)).”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [135]
Semaglutide 2.4 mg subcutaneous once-weekly treatment has been demonstrated to provide significant and sustained mean weight loss of up to 16%, significant CV risk factor improvements, and proven CV benefit in patients with diabetes and prior CV events.
“The study uses standard‐of‐care preventive measures along with semaglutide 2.4 mg subcutaneous once‐weekly treatment, which has been demonstrated to provide significant and sustained mean weight loss of up to 16% [10, 11, 12, 13, 24, 25], significant CV risk factor improvements, and proven CV benefit in patients with diabetes and prior CV events [16, 26].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: <scp>SELECT</scp> study baseline characteristics (2023) · cites this paper as [25]
Weight loss greater than 10% was achieved in 70.9% of semaglutide-treated patients and 25.6% of liraglutide-treated patients, with comparable rates of gastrointestinal adverse events.
“A weight loss greater than 10% (therapeutic target in NAFLD) was achieved in 70.9% of semaglutide-treated patients and 25.6% of liraglutide-treated patients, with comparable rates of gastrointestinal adverse events [46].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [46]
In the STEP 8 randomized clinical trial, semaglutide 2.4 mg/week achieved a mean weight loss of 15.8% after 68 weeks compared with 6.4% with liraglutide.
“Notably, in the recent STEP 8 randomized clinical trial [46], semaglutide (2.4 mg/week) achieved a mean weight loss of 15.8% after 68 weeks of treatment compared with 6.4% obtained with liraglutide.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [46]
The STEP trial programme assessed the effect of a high dose of the GLP-1 receptor agonist semaglutide (2.4 mg once weekly by subcutaneous injection) and typically noted about a 15% reduction in body weight during treatment periods up to 2 years in overweight and obese adults who did not have type 2 diabetes.
“The STEP trial programme assessed the effect of a high dose of the GLP-1RA semaglutide (2.4 mg once weekly by subcutaneous injection: Weygovy ) and typically noted about a 15% reduction in body weight during treatment periods up to 2 years in overweight and obese adults who did not have T2DM (STEP-1, 3, 4, 5, 8) [16-23].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [22]
Semaglutide leads to greater weight loss than liraglutide.
“Semaglutide compared to liraglutide resulted in greater weight loss.”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [19]
The FDA efficacy benchmark criteria for weight-management products were met in the STEP 1, STEP 3, STEP 4, and STEP 8 trials of semaglutide.
“Both efficacy benchmark criteria for weight management products were met in STEP 1, 3, 4 and 8 trials [15–17, 19].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [19]
In people without diabetes, liraglutide 3.0 mg produces a mean weight loss 3.4% to 6.1% greater than placebo.
“Liraglutide resulted in 3.4 to 6.1% difference in mean weight loss compared to placebo [10–14, 19].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [19]
In people without diabetes, semaglutide 2.4 mg produces a mean weight loss 10.3% to 17.4% greater than placebo.
“Semaglutide resulted in 10.3–17.4% difference in mean weight compared to placebo [15–17, 19].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [19]
In people without diabetes, 50.5% to 73% of those treated with liraglutide lose at least 5% of baseline body weight.
“The proportion of subjects who lost ≥ 5% of baseline body weight was 50.5–73% [10–14, 19].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [19]
In people without diabetes, 86.4% to 88.7% of those treated with semaglutide lose at least 5% of baseline body weight.
“The proportion of subjects who lost ≥ 5% of baseline body weight was 86.4–88.7% [15–17, 19].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [19]
The placebo-adjusted weight loss and adverse effect profiles in STEP 8 were similar to those in STEP 1 for semaglutide and to SCALE Obesity and Prediabetes for liraglutide.
“The placebo-adjusted weight loss and adverse effect profiles were similar to those in STEP 1 for semaglutide and to SCALE Obesity and Prediabetes for liraglutide [19].”
From Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) · cites this paper as [19]
Main published trials (STEP 1 through STEP 5, STEP 8, and STEP TEENS) did not include participants who reported symptoms of major depressive disorder within 2 years before screening, limiting their ability to assess psychiatric adverse events in people with a recent history of depression.
“the main trials for which data have been published (STEP 1 through STEP 5, STEP 8, and STEP TEENS) did not include participants who reported having symptoms of major depressive disorder within 2 years before screening, which limits their ability to assess psychiatric adverse events in people with a recent history of depression [3,4,93,94,95,96,97].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [3]
In SURMOUNT-1, tirzepatide 15 mg weekly induced a mean weight reduction of up to −20.9% at 72 weeks in individuals with obesity and without type 2 diabetes, compared with −3.1% with placebo.
“In SURMOUNT-1, tirzepatide 15 mg weekly induced a mean weight reduction of up to −20.9% at 72 weeks in individuals with obesity and without T2DM, compared with −3.1% with placebo [21].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [21]
Semaglutide added to counseling for diet and physical activity resulted in an average weight loss of 15.8% compared to 6.4% with liraglutide.
“Semaglutide, added to counseling for diet and PA, resulted in an average WL of 15.8% compared to 6.4% with liraglutide.”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [21]
STEP 8 observed mean 68-week reductions in baseline weight of 15.8% with semaglutide versus 6.4% with liraglutide 3.0 mg and 1.9% for pooled placebo.
“STEP 8 observed mean 68-week reductions in baseline weight of 15.8% with semaglutide versus 6.4% with liraglutide 3.0 mg (and 1.9% for pooled placebo) [55].”
From The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023) · cites this paper as [55]
In the STEP8 trial, comparing semaglutide 2.4 mg weekly with liraglutide 3.0 mg daily in patients with overweight or obesity and no prior bariatric surgery or type 2 diabetes, mean weight change from baseline was −15.8% with semaglutide versus −6.4% with liraglutide after 68 weeks.
“In the STEP8 trial, comparing semaglutide (2.4 mg, weekly subcutaneous injection) with liraglutide (3.0 mg, daily subcutaneous injection) in patients with overweight or obesity and no previous bariatric surgery or T2D, a mean weight change from baseline of −15.8% with semaglutide vs −6.4% with liraglutide after 68 weeks was reported [27].”
In a comparison of weekly subcutaneous semaglutide 2.4 mg versus daily subcutaneous liraglutide 3.0 mg in patients with overweight or obesity without type 2 diabetes, total body weight loss was 15.8% with semaglutide and 6.4% with liraglutide after 68 weeks.
“The latest published results comparing weight loss with weekly subcutaneous semaglutide (2.4 mg) vs daily subcutaneous liraglutide (3.0 mg) in patients with overweight or obesity without T2D demonstrated a total body weight loss of 15.8% with semaglutide vs 6.4% with liraglutide after 68 weeks of therapy [27].”
Across the phase 3 STEP program, semaglutide 2.4 mg subcutaneously weekly plus lifestyle modification in people with obesity without type 2 diabetes produced body weight reduction from baseline ranging from 12.1% to 18.2%.
“Across the phase 3 STEP program for semaglutide 2.4 mg s.c.weekly plus lifestyle modification in individuals living with obesity without T2D, the body weight reduction from baseline ranged from 12.1% to 18.2%.107-113”
From Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists (2024) · cites this paper as [110]
In STEP 8, weekly semaglutide 2.4 mg was superior to daily liraglutide 3.0 mg, with a treatment difference of -9.4% body weight.
“The more recently published STEP 8 trial demonstrates the superiority of weekly semaglutide 2.4 mg versus daily liraglutide 3.0 mg (treatment difference -9.4% body weight) (37).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [37]
Gastrointestinal serious AEs were reported in nine publications including the SCALE, STEP, and SURMOUNT clinical studies.
“Gastrointestinal serious AEs (SAEs) were reported in nine publications [12,36,52,81,85,89,94,98,103] including the SCALE (liraglutide), STEP (semaglutide), and SURMOUNT (tirzepatide) clinical studies.”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [85]
In STEP 8, severe GI AEs were reported in 2.4% of patients treated with liraglutide and 3.2% of patients treated with semaglutide.
“In STEP 8 [85], severe GI AEs were reported in 2.4% and 3.2% of patients treated with liraglutide and semaglutide, respectively.”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [85]
There was one publication where the incidence of diarrhea was greater in the placebo than the liraglutide arm.
“There was one publication where the incidence of diarrhea was greater in the placebo than the liraglutide arm [85].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [85]
SAEs occurring in >5% of patients were reported in 26 studies, with 9 publications reporting SAEs in >10% of patients.
“SAEs occurring in >5% of patients were reported in 26 studies [11][12][13][14]35,40,42,51,52,58,62,63,[65][66][67]70,74,77,[84][85][86]93,94,96,103,104], with 9 publications reporting SAEs in >10% of patients [11,14,66,67,85,86,89,103,104].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [85]
Semaglutide was significantly more effective in weight loss than liraglutide for overweight or obesity without diabetes, and it also exhibited excellent effect in East Asian populations.
“Recent studies have shown that semaglutide was significantly more effective in weight loss than liraglutide for overweight or obesity without diabetes, and it also exhibited excellent effect in East Asian populations (34, 35).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Self-citation2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603 · see citing works
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506 · see citing works
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · see citing works
Self-citationWadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · see citing works
Self-citationDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · see citing works
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842 · see citing works
Self-citationon behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · see citing works
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 2× · see citing works
“However, the reduction in caloric intake vs placebo appears to be larger with semaglutide (35%) than liraglutide (approximately 16%).(19,20)Semaglutidehasalso beenassociatedwith reductions in foodcravings,which is less evident with liraglutide, suggesting different mechanisms of energy intake regulation.”
BackgroundFriedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427 · see citing works
Self-citationCapehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412 · see citing works
Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.008 · Cited by 249 · cited 1× · see citing works
“Whether semaglutide could be beneficial in preventing progressionof cardiometabolicdiseasewill beevaluated in the SELECT trial (NCT03574597).(28) The rates of AEs, which were mostly gastrointestinalrelated, were similar with semaglutide and liraglutide in this trial, consistent with previous trials.”
ResultChao, A. M., Wadden, T. A., Walsh, O. A., Gruber, K. A., Alamuddin, N., Berkowitz, R. I., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22653 · Cited by 84 · see citing works
Self-citationWharton, S., Astrup, A., Endahl, L., Lean, M. E. J., Satylganova, A., Skovgaard, D., Wadden, T. A., & Wilding, J. P. H. (2021) · International Journal of Obesity · doi:10.1038/s41366-020-00733-x · Cited by 58 · see citing works
Self-citationGatekeeping Strategies for Avoiding False-Positive Results in Clinical Trials With Many Comparisons
Yadav, K., & Lewis, R. (2017) · JAMA · doi:10.1001/jama.2017.13276 · Cited by 38 · see citing works
Missing data in clinical trials for weight management.
McEvoy, B. W. (2016) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2015.1094814 · Cited by 27 · see citing works
Flagged first, then by citations
Research works printed but not linked: 9
- [2]2. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/ NEJMoa2032183
- [7]7. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. doi:10.3389/ fendo.2019.00155
- [15]15. Little RJA, Rubin D B. Statistical Analysis With Missing Data. John Wiley & Sons; 1987.
- [24]24. Divino V, Ramasamy A, Anupindi VR, et al. Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study. J Manag Care Spec Pharm. 2021;27(2):210-222. doi:10.18553/jmcp. 2020.20272 · DOI
- [25]25. Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. Pharmacoeconomics. 2015;33(7):707-722. doi:10. 1007/s40273-014-0230-2
- [29]29. Davies MJ, Bergenstal R, Bode B, et al; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA. 2015;314(7):687-699. doi:10.1001/ jama.2015.9676
- [30]30. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. doi:10.1038/ijo. 2016.52 · DOI
- [31]31. O'Neil PM, Aroda VR, Astrup A, et al; Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19(11):1529-1536. doi:10. 1111/dom.12963
- [33]33. Hauber AB, Nguyen H, Posner J, Kalsekar I, Ruggles J. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2016;32(2):251-262. doi:10.1185/03007995.2015. 1117433 · DOI
Cited by
Sorted by citations
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473 · see citing works
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598 · see citing works
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868 · see citing works
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596 · see citing works
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462 · see citing works
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471 · see citing works
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440 · see citing works
Self-citationAhmed, S. K., & Mohammed, R. A. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100375 · Cited by 432 · see citing works
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347 · see citing works
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313 · see citing works
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286 · see citing works
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280 · see citing works
Semaglutide for the treatment of overweight and obesity: A review
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14863 · Cited by 265 · see citing works
Medications for Obesity: A Review
Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263 · see citing works
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280 · see citing works
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248 · see citing works
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31982 · Cited by 238 · see citing works
Obesity and cardiovascular health
Welsh, A., Hammad, M., Piña, I. L., & Kulinski, J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae025 · Cited by 239 · see citing works
Jensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215 · see citing works
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207 · see citing works
Mok, J., Adeleke, M. O., Brown, A., Magee, C. G., Firman, C., Makahamadze, C., Jassil, F. C., Marvasti, P., Carnemolla, A., Devalia, K., et al. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.2930 · Cited by 178 · see citing works
McGowan, B. M., Bruun, J. M., Capehorn, M., Pedersen, S. D., Pietiläinen, K. H., Muniraju, H. A. K., Quiroga, M., Varbo, A., & Lau, D. C. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00182-7 · Cited by 176 · see citing works
Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.23332 · Cited by 172 · see citing works
Jensen, A. B., Renström, F., Aczél, S., Folie, P., Biraima-Steinemann, M., Beuschlein, F., & Bilz, S. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06484-8 · Cited by 161 · see citing works
New insights into the treatment of obesity
Blüher, M., Aras, M., Aronne, L. J., Batterham, R. L., Giorgino, F., Ji, L., Pietiläinen, K. H., Schnell, O., Tonchevska, E., & Wilding, J. P. H. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15077 · Cited by 158 · see citing works
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152 · see citing works
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149 · see citing works
Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024) · Scientific Reports · doi:10.1038/s41598-024-75965-2 · Cited by 143 · see citing works
Alkhezi, O. S., Alahmed, A. A., Alfayez, O. M., Alzuman, O. A., Almutairi, A. R., & Almohammed, O. A. (2023) · Obesity Reviews · doi:10.1111/obr.13543 · Cited by 139 · see citing works
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145 · see citing works
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129 · see citing works
Self-citationKosiborod, M. N., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Khalid, U., Kushner, R., Rubino, D. M., Zeuthen, N., & Verma, S. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14890 · Cited by 127 · see citing works
Self-citationLingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity · doi:10.1002/oby.23621 · Cited by 113 · see citing works
Ansari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112 · see citing works
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111 · see citing works
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123 · see citing works
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101 · see citing works
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102 · see citing works
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102 · see citing works
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103 · see citing works
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100 · see citing works
Xie, Z., Yang, S., Deng, W., Li, J., & Chen, J. (2022) · Clinical Epidemiology · doi:10.2147/clep.s391819 · Cited by 93 · see citing works
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231165169 · Cited by 88 · see citing works
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86 · see citing works
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99 · see citing works
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935823 · Cited by 81 · see citing works
Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.7.740 · Cited by 81 · see citing works
What Is Food Noise? A Conceptual Model of Food Cue Reactivity
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023) · Nutrients · doi:10.3390/nu15224809 · Cited by 80 · see citing works
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185915 · Cited by 83 · see citing works
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68 · see citing works
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., Butsch, W. S., & Rothberg, M. B. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.33326 · Cited by 71 · see citing works
Semaglutide vs endoscopic sleeve gastroplasty for weight loss
Haseeb, M., Chhatwal, J., Xiao, J., Jirapinyo, P., & Thompson, C. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6221 · Cited by 73 · see citing works
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73 · see citing works
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15386 · Cited by 72 · see citing works
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68 · see citing works
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69 · see citing works
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66 · see citing works
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65 · see citing works
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58 · see citing works
Self-citationAnti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57 · see citing works
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90 · see citing works
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54 · see citing works
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56 · see citing works
Case Report: Semaglutide-associated depression: A report of two cases
Li, J.-R., Cao, J., Wei, J., & Geng, W. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1238353 · Cited by 50 · see citing works
Obesity pharmacotherapy in older adults: a narrative review of evidence
Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01529-z · Cited by 51 · see citing works
Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01150-8 · Cited by 50 · see citing works
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48 · see citing works
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae384 · Cited by 44 · see citing works
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44 · see citing works
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 43 · see citing works
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44 · see citing works
Pharmacologic management of weight regain following bariatric surgery.
Lucas, E., Simmons, O., Tchang, B., & Aronne, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043595 · Cited by 41 · see citing works
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43 · see citing works
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39 · see citing works
Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
Rodríguez Jiménez, B., Rodríguez de Vera Gómez, P., Belmonte Lomas, S., Mesa Díaz, Á. M., Caballero Mateos, I., Galán, I., Morales Portillo, C., & Martínez-Brocca, M. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1386542 · Cited by 39 · see citing works
Leite, A. R., Angélico‐Gonçalves, A., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite‐Moreira, A., Neves, J. S., & Ferreira, J. P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14707 · Cited by 39 · see citing works
Gasoyan, H., Pfoh, E. R., Schulte, R., Sullivan, E., Le, P., & Rothberg, M. B. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15473 · Cited by 41 · see citing works
Hropot, T., Herman, R., Janez, A., Lezaic, L., & Jensterle, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108592 · Cited by 39 · see citing works
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36 · see citing works
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35 · see citing works
le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15148 · Cited by 36 · see citing works
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
Ghusn, W., Fansa, S., Anazco, D., Tama, E., Nicolalde, B., Gala, K., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., et al. (2024) · International Journal of Obesity · doi:10.1038/s41366-023-01456-5 · Cited by 35 · see citing works
Atlas, S. J., Kim, K., Nhan, E., Touchette, D. R., Moradi, A., Agboola, F., Rind, D. M., Beaudoin, F. L., & Pearson, S. D. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.569 · Cited by 33 · see citing works
Stefanou, M.-I., Palaiodimou, L., Theodorou, A., Safouris, A., Fischer, U., Kelly, P. J., Dawson, J., Katan, M., Katsanos, A. H., Lambadiari, V., et al. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241281903 · Cited by 36 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31 · see citing works
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30 · see citing works
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25 · see citing works
Wilkinson, L., Holst‐Hansen, T., Laursen, P. N., Rinnov, A. R., Batterham, R. L., & Garvey, W. T. (2023) · Obesity · doi:10.1002/oby.23842 · Cited by 25 · see citing works
Self-citationPharmacological Treatment of Obesity in Older Adults
Žižka, O., Haluzík, M., & Jude, E. B. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01150-9 · Cited by 23 · see citing works
Semaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23 · see citing works
Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy
Ahmad, A. I., Garg, S., Jacobs, J., Ansari, Z., Al-Din, T. J., Almomani, A., Valencia, S., Vargo, J., Chatterjee, A., Siddiki, H., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.0027 · Cited by 24 · see citing works
Alabduljabbar, K., Alsaqaaby, M., Neff, K. J., Crotty, M., & le Roux, C. W. (2023) · Endocrine · doi:10.1007/s12020-023-03534-0 · Cited by 16 · see citing works
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., Gallen, I. W., Field, B. C. T., Idris, I., Ryder, R. E. J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14701 · Cited by 14 · see citing works
Titration and discontinuation of semaglutide for weight management in commercially insured US adults
Xu, Y., Carrero, J. J., Chang, A. R., Inker, L. A., Zhang, D., Mukhopadhyay, A., Blecker, S. B., Horwitz, L. I., Grams, M. E., & Shin, J. (2025) · Obesity · doi:10.1002/oby.24315 · Cited by 16 · see citing works
Kumar, N., & D’Alessio, D. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac276 · Cited by 14 · see citing works
Exercise for Clients Taking an Anti-Obesity Medication
Rogers, R. J. (2024) · ACSM'S Health & Fitness Journal · doi:10.1249/fit.0000000000000959 · Cited by 12 · see citing works
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13 · see citing works
Tirzepatide: Clinical review of the twincretin injectable
Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12 · see citing works
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15 · see citing works
Singh, A., Singh, A. K., Singh, R., & Misra, A. (2025) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103212 · Cited by 10 · see citing works
- Authors
- Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, Arauz-Pacheco, C., Cannon, K., Downey, H. J., Fitz-Patrick, D., Geohas, J., Gerety, G., Gilbert, J., Hollander, P., Klein, E., Laufer, K., O'Donnell, P., Rosenblit, P., & Toth, P.
- Affiliations
- Washington Center for Weight Management and Research (US)
- Pennington Biomedical Research Center (US)
- Novo Nordisk (Denmark) (DK)
- Medical University of South Carolina (US)
- Dallas Diabetes Research Center (US)
- University of Pennsylvania (US)
- University of Alabama at Birmingham (US)
- for the STEP 8 Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2022-01-11
- Volume
- 327
- Issue
- 2
- Pages
- 138
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8753508
- OpenAlex
- W4205651374
- Semantic Scholar
- 56b4098607c08055ced28201457412e05e174c6f
- Cited by
- 995
- References
- 18
- Citations by year
- 2026: 200 · 2025: 274 · 2024: 259 · 2023: 187 · 2022: 74 · 2014: 1
- FWCI
- 118.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056336)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- semaglutide, liraglutide, GLP-1 receptor agonists, obesity, overweight, weight loss, weight-related comorbidities, adverse events, drug safety, dose escalation, placebo comparison, open-label extension, GLP-1 receptor antagonists, weight regain after weight loss
- MeSH terms
- Liraglutide, Semaglutide, Body Weight, Diabetes Mellitus, Diet Therapy, Drug Administration Schedule, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Obesity, Patient Dropouts, Placebos, United States, Weight Loss, Exercise, Odds Ratio, Treatment Outcome, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
